After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.